Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)
Close on Nov 17, 2026Market cap $1.70BP/E –Yield –
Stoke Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Stoke Therapeutics's price to book ratio was 5.0× on Nov 11, 2026, against 5.5× a year earlier. Over the last 5 years it ranged from 0.9× to 6.1×, with a median of 2.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.0× | −0.7 |
| 2025 | Dec 31, 2025 | 5.7× | +3.2 |
| 2024 | Dec 31, 2024 | 2.5× | +1.2 |
| 2023 | Dec 29, 2023 | 1.3× | −0.4 |
| 2022 | Dec 30, 2022 | 1.8× | −1.9 |
| 2021 | Dec 31, 2021 | 3.7× | −7.0 |
| 2020 | Dec 31, 2020 | 10.7× | +6.8 |
| 2019 | Dec 31, 2019 | 4.0× | – |
See a number that looks wrong?